Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 48

Sort by

Sort Order Select

Journal Articles

Insights into the Natural History and Treatment Outcomes of Hemophagocytic Lymphohistiocytosis (INTO-HLH) Patient Registry: Study Design and Clinical Characteristics

Adi Zoref-Lorenz, David C. Fajgenbaum, Shanna Korn, Tayloranne Kaufmann, Brady Anderson, Abiola Oladapo, Laura Saltonstall, Deanna Fournier, Edward Behrens, Carl E Allen, Michael B. Jordan

Blood (2024) 144 (Supplement 1): 5389.

https://doi.org/10.1182/blood-2024-209715

Published: 2024

Journal Articles

The Development of Diagnostic Criteria and Utilization of Excisional Lymph Node Biopsies Shorten Time to Diagnosis for Idiopathic Multicentric Castleman Disease

Mateo Sarmiento Bustamante, Criswell L. M. Lavery, Adam Bagg, Mary Jo Lechowicz, Daisy V. Alapat, Amy Chadburn, Megan S Lim, Gordan Srkalovic, Frits van Rhee, Joshua D Brandstadter, David C. Fajgenbaum

Blood (2024) 144 (Supplement 1): 1156.

https://doi.org/10.1182/blood-2024-211190

Published: 2024

Journal Articles

Lymph Node Transcriptomics in Idiopathic Multicentric Castleman Disease (iMCD) Identifies Pathogenic Mechanisms and Biomarkers Including Increased Clusterin Expression

Michael V. Gonzalez, Melanie D. Mumau, Joseph M. Zinski, Abiola Irvine, Joshua D Brandstadter, Sheila K. Pierson, Bridget Austin, David C. Fajgenbaum

Blood (2024) 144 (Supplement 1): 3923.

https://doi.org/10.1182/blood-2024-210547

Published: 2024

Journal Articles

Myofibroblast to T-Zone Reticular Cell Ratio Identifies Unicentric Castleman Disease Lymph Nodes

Joshua D Brandstadter, Mechthild Lutge, Megan S Lim, Adam Bagg, Ira D. Miller, Michael V. Gonzalez, Bridget Austin, Salvatore F. Priore, Burkhard Ludewig, David C. Fajgenbaum, Ivan Maillard

Blood (2024) 144 (Supplement 1): 1155.

https://doi.org/10.1182/blood-2024-211070

Published: 2024

Journal Articles

Trafficking, Not Lymphoproliferation, Promotes Lymphadenopathy in Idiopathic Multicentric Castleman Disease

Melanie D. Mumau, Criswell L. M. Lavery, Abiola Irvine, Joseph M. Zinski, M. Betina Pampena, Ira D. Miller, Michael V. Gonzalez, Michael R. Betts, David C. Fajgenbaum

Blood (2024) 144 (Supplement 1): 3924.

https://doi.org/10.1182/blood-2024-210726

Published: 2024

Journal Articles

The Role of CABIN1 in the Pathogenesis of Idiopathic Multicentric Castleman Disease

Dorottya Laczko, David C. Fajgenbaum, Taku Kambayashi

Blood (2023) 142 (Supplement 1): 3920.

https://doi.org/10.1182/blood-2023-182283

Published: 2023

Journal Articles

Identification of Autoantibodies Associated with Connective Tissue Disorders in Idiopathic Multicentric Castleman Disease

Allan Feng, Michael V. Gonzalez, Melanie Mumau, Saishravan Shyamsundar, Paul J. Utz, David C. Fajgenbaum

Blood (2023) 142 (Supplement 1): 1993.

https://doi.org/10.1182/blood-2023-189788

Published: 2023

Journal Articles

Clinical Characteristics, Treatment Trends, and Outcomes of Patients with HHV-8-Negative/Idiopathic Multicentric Castleman Disease Treated with Siltuximab in a Machine Learning-Selected Real-World Cohort

Aaron B Cohen, Melissa Estevez, Jonathan G Kelly, James N Gippetti, Erin L Fidyk, Joshua D. Brandstadter, David C. Fajgenbaum

Blood (2023) 142 (Supplement 1): 907.

https://doi.org/10.1182/blood-2023-174924

Published: 2023

Journal Articles

Exploratory Analyses of Lymph Node Tissue, Serum, and Peripheral Blood Mononuclear Cells Do Not Reveal Pathogen Signatures in Idiopathic Multicentric Castleman Disease

Ira Miller, Daniel Jose Arenas, Melanie Mumau, Michael V. Gonzalez, David C. Fajgenbaum

Blood (2023) 142 (Supplement 1): 4402.

https://doi.org/10.1182/blood-2023-188991

Published: 2023

Journal Articles

Clinical Characteristics and Treatment Outcomes of Idiopathic Multicentric Castleman Disease: Data from a Pediatric Cohort

Saishravan Shyamsundar, Mateo Sarmiento Bustamante, Sheila K. Pierson, Joshua D. Brandstadter, Frits van Rhee, David C. Fajgenbaum

Blood (2023) 142 (Supplement 1): 4415.

https://doi.org/10.1182/blood-2023-183039

Published: 2023

Journal Articles

A Translational Approach to Identifying and Targeting TNF Signaling in Idiopathic Multicentric Castleman Disease

Melanie Mumau, Abiola Irvine, Chunyu Ma, Sheila K. Pierson, Brent Shaw, Michael V. Gonzalez, Daniel Korn, Tracey Sikora, Grant Mitchell, David Koslicki, Luke Y. C. Chen, David C. Fajgenbaum

Blood (2023) 142 (Supplement 1): 3921.

https://doi.org/10.1182/blood-2023-188076

Published: 2023

Journal Articles

Immune Checkpoint Inhibitors and the Risk of Cardiovascular Adverse Events: A Pooled Clinical Trial Database Analysis

Kayleen Ports, Rahul Jain, Sheila Diamond, Jacob Aptekar, David C. Fajgenbaum

Blood (2023) 142 (Supplement 1): 6933.

https://doi.org/10.1182/blood-2023-181968

Published: 2023

Journal Articles

Longitudinal, Real-World Data Reveal Treatment Effectiveness in Idiopathic Multicentric Castleman Disease and Support Current Treatment Guidelines

Sheila K Pierson, Mateo Sarmiento Bustamante, Joshua D Brandstadter, Daisy Alapat, Adam Bagg, Mary Jo Lechowicz, Gordan Srkalovic, Megan S. Lim, Frits van Rhee, David C Fajgenbaum

Blood (2022) 140 (Supplement 1): 9378–9379.

https://doi.org/10.1182/blood-2022-170360

Published: 2022

Journal Articles

Insights into the Natural History and Treatment Outcomes of Hemophagocytic Lymphohistiocytosis (HLH): The into-HLH Registry

Adi Zoref-Lorenz, David C. Fajgenbaum, Sheila K. Pierson, Abiola Oladapo, John Yee, Nitya Gulati, Carl E. Allen, Michael B. Jordan

Blood (2022) 140 (Supplement 1): 11170–11171.

https://doi.org/10.1182/blood-2022-170288

Published: 2022

Journal Articles

Increased Comorbidities and Hospitalizations Associated with Idiopathic Multicentric Castleman Disease

Mateo Sarmiento Bustamante, Sheila K Pierson, Yue Ren, Daisy Alapat, Adam Bagg, Joshua D Brandstadter, Mary Jo Lechowicz, Hongzhe Lee, Gordan Srkalovic, Megan S. Lim, Frits van Rhee, David C Fajgenbaum

Blood (2022) 140 (Supplement 1): 6520–6521.

https://doi.org/10.1182/blood-2022-170102

Published: 2022

Journal Articles

Deriving Predictive Features of Severe CRS from Pre-Infusion Clinical Data in CAR T-Cell Therapies

Vibhu Agarwal, Jacob Aptekar, David C Fajgenbaum, Penelope Lafeuille

Blood (2022) 140 (Supplement 1): 7838–7839.

https://doi.org/10.1182/blood-2022-169287

Published: 2022

Journal Articles

A Novel Cryopreservation and Biobanking Strategy to Study Lymphoid Tissue Stromal Cells in Lymphoproliferative Disorders

Joshua D Brandstadter, Angelina De Martin, Mechthild Lϋetge, Antonio Ferreira, Brian T. Gaudette, Michael Gonzalez, Yves Stanossek, Edward Camiolo, Gerald Wertheim, David Allman, David C Fajgenbaum, Jon C. Aster, Burkhard Ludewig, Ivan Maillard

Blood (2022) 140 (Supplement 1): 3562–3563.

https://doi.org/10.1182/blood-2022-159835

Published: 2022

Journal Articles

Serum Proteomics Identifies Interferon Gamma Signaling in Idiopathic Multicentric Castleman Disease

Melanie Mumau, Sheila K Pierson, Michael Gonzalez, Scott Canna, David C Fajgenbaum

Blood (2022) 140 (Supplement 1): 5500–5501.

https://doi.org/10.1182/blood-2022-167829

Published: 2022

Journal Articles

Association between Insufficient Interleukin-6 (IL-6) Inhibition and Worsening Outcomes in COVID-19 and Idiopathic Multicentric Castleman Disease (iMCD), and a Mathematical Model to Predict Optimal Dosing to Completely Block IL-6 Activity

Jean-Francois Rossi, Hao-Chun Chiang, Zhao-Yang Lu, Kalle Levon, Frits van Rhee, Karan Kanhai, David C Fajgenbaum, Bernard Klein

Blood (2021) 138 (Supplement 1): 4004.

https://doi.org/10.1182/blood-2021-150433

Published: 2021

Journal Articles

Increased mTORC2 Pathway Activation in Lymph Nodes of Imcd-Tafro

Alexis D Phillips, Joseph K Kakkis, Patricia Y Tsao, Sheila K Pierson, David C Fajgenbaum

Blood (2021) 138 (Supplement 1): 4316.

https://doi.org/10.1182/blood-2021-146821

Published: 2021

NARROW

Insights into the Natural History and Treatment Outcomes of Hemophagocytic Lymphohistiocytosis (INTO-HLH) Patient Registry: Study Design and Clinical Characteristics

The Development of Diagnostic Criteria and Utilization of Excisional Lymph Node Biopsies Shorten Time to Diagnosis for Idiopathic Multicentric Castleman Disease

Lymph Node Transcriptomics in Idiopathic Multicentric Castleman Disease (iMCD) Identifies Pathogenic Mechanisms and Biomarkers Including Increased Clusterin Expression

Myofibroblast to T-Zone Reticular Cell Ratio Identifies Unicentric Castleman Disease Lymph Nodes

Trafficking, Not Lymphoproliferation, Promotes Lymphadenopathy in Idiopathic Multicentric Castleman Disease

The Role of CABIN1 in the Pathogenesis of Idiopathic Multicentric Castleman Disease

Identification of Autoantibodies Associated with Connective Tissue Disorders in Idiopathic Multicentric Castleman Disease

Clinical Characteristics, Treatment Trends, and Outcomes of Patients with HHV-8-Negative/Idiopathic Multicentric Castleman Disease Treated with Siltuximab in a Machine Learning-Selected Real-World Cohort

Exploratory Analyses of Lymph Node Tissue, Serum, and Peripheral Blood Mononuclear Cells Do Not Reveal Pathogen Signatures in Idiopathic Multicentric Castleman Disease

Clinical Characteristics and Treatment Outcomes of Idiopathic Multicentric Castleman Disease: Data from a Pediatric Cohort

A Translational Approach to Identifying and Targeting TNF Signaling in Idiopathic Multicentric Castleman Disease

Immune Checkpoint Inhibitors and the Risk of Cardiovascular Adverse Events: A Pooled Clinical Trial Database Analysis

Longitudinal, Real-World Data Reveal Treatment Effectiveness in Idiopathic Multicentric Castleman Disease and Support Current Treatment Guidelines

Insights into the Natural History and Treatment Outcomes of Hemophagocytic Lymphohistiocytosis (HLH): The into-HLH Registry

Increased Comorbidities and Hospitalizations Associated with Idiopathic Multicentric Castleman Disease

Deriving Predictive Features of Severe CRS from Pre-Infusion Clinical Data in CAR T-Cell Therapies

A Novel Cryopreservation and Biobanking Strategy to Study Lymphoid Tissue Stromal Cells in Lymphoproliferative Disorders

Serum Proteomics Identifies Interferon Gamma Signaling in Idiopathic Multicentric Castleman Disease

Association between Insufficient Interleukin-6 (IL-6) Inhibition and Worsening Outcomes in COVID-19 and Idiopathic Multicentric Castleman Disease (iMCD), and a Mathematical Model to Predict Optimal Dosing to Completely Block IL-6 Activity

Increased mTORC2 Pathway Activation in Lymph Nodes of Imcd-Tafro

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only